EX-4.27 2 ex427amendment-tuchman.htm AMENDMENT - TUCHMAN

EX. 4.27 Amendment - Tuchman

AMENDING AGREEMENT NO. 1

THIS AMENDING AGREEMENT made effective as of the 12^th day of March, 2015.

BETWEEN:

ONCOYLYTICS BIOTECH (U.S.), INC.,

("OBUS")

- and -

ALAN J. TUCHMAN, M.D.

(the "Employee")

WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Executive Employment Agreement ("Employment Agreement") dated effective September 27, 2012;

AND WHEREAS OBUS and the Employee wish to amend the Employment Agreement;

NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:

Section 1 – Amendments

The Employment Agreement is hereby amended by replacing Section 3(1) with the following:

“Commencing January 1, 2015, OBUS shall pay to the Employee a salary of ONE HUNDRED FORTY-SIX THOUSAND SIX HUNDRED SIXTY-NINE DOLLARS AND THIRTY-SEVEN CENTS ($146,669.37) U.S. DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of SIX THOUSAND ONE HUNDRED ELEVEN DOLLARS AND TWENTY-TWO CENTS ($6,111.22) U.S. DOLLARS on the 15^th and last day of each month.”

Section 2 – Effective Date

(1)    This Amending Agreement shall be effective from and after January 1, 2015.

(2)    In all other respects the parties confirm that the Employment Agreement, as amended, shall remain in full force and effect.

		ONCOLYTICS BIOTECH (U.S.), INC.
		Per:	/s/ Mary Ann Dillahunty
			Mary Ann Dillahunty President
		Per:	/s/ Kirk Look
			Kirk Look Chief Financial Officer

/s/ Margaret Kowalczewski		/s/ Alan J. Tuchman
WITNESS		ALAN J. TUCHMAN, M.D.